Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
NGHIÊN CỨU LÂM SÀNG Issue: Số 68 (2014) TĂNG HUYẾT ÁP

No translate

Published: October 31, 2014
Views: 572

Abstract

Aim: To determine the characteristics of hypertension (HBP) in patients with gout. Subjects and Methods: Cross-sectional study. 94 gouty patients were diagnosed with gout using the ILAR and OMERACT 2000 criteria, HBP using the WHO/ISH 2003 criteria, and metabolic syndrome (MS) using the Asian NCEP ATPIII criteria. Result: The male/female ratio was 10:1, the average age was 62.5 ± 13.3; 59.6% of gouty patients were older than 60. 80.8% of gouty patients had HBP. There was no statistically significant difference in HBP ratio between gouty patients aged ≥ 60 and < 60. The characteristics of HBP in patients with gout: 55.2% systolic hypertension, hypertension stage 2: 46.1%; stage 3: 32.9%. The group of gouty patients with HBP usually had more tophi and swollen painful joints than those without HBP. The patients with HBP and gout also had a longer gout duration than patients with gout only (p < 0.05). The ratio and level of hyperuricemia in gouty patients with HBP were higher than in the group without HBP. Conclusion: HBP is highly prevalent in gouty patients. Gouty patients with HBP usually have hyperuricemia, polyarthritis and tophi more than gouty patients without HBP.

Keywords
hypertension gout metabolic syndrome uric acid tophus

References

1.
1. (2001), “Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)”, JAMA, 285 (19), pp. 2486 - 2497.
2.
2. Hồ Thị Thanh Tâm , Ngô Thế Hoàng, Nguyễn Đức Công(2013), “Đặc điểm của bệnh Goute ở người lớn tuổi tại khoa nội cơ xương khớp bệnh viện Thống Nhất”, Y học TP. Hồ Chí Minh, 17 (Phụ bản số 3), pp. 270-4.
3.
3. Trịnh Kiến Trung, Lê Anh Thư (2010), “Hội chứng chuyển hóa ở bệnh nhân viêm khớp goute”, Nghiên cứu y học, phụ bản số 3, pp. 455-9.
4.
4. Brooks P., Hochberg M., ILAR for, OMERACT (2001), “Outcome measures and classification criteria for the rheumatic diseases. A compilation of data from OMERACT (Outcome Measures for Arthritis Clinical Trials), ILAR (International League of Associations for Rheumatology), regional leagues and other groups”, Rheumatology, 40 (8), pp. 896-906.
5.
5. Choi H. K., Atkinson K., Karlson E. W., Curhan G. (2005), “Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study”, Arch Intern Med, 165 (7), pp. 742-8.
6.
6. Choi H. K., Ford E. S., Li C., Curhan G. (2007), “Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey”, Arthritis Rheum, 57 (1), pp. 109-15.
7.
7. Choi Hyon K, Soriano Lucia Cea, Zhang yuqing, Rodríguez Luis A García (2012), Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study, Vol. 344.
8.
8. Fraile J. M., Torres R. J., de Miguel Mendieta E., Martínez P., Lundelin K. J., Vázquez J. J., Puig J. G. (2010), “Metabolic Syndrome Characteristics in Gout Patients”, Nucleosides, Nucleotides and Nucleic Acids, 29 (4-6), pp. 325-329.
9.
9. Surayo Shukurova Khisrav Toirov, Nabijon Hamidov, Dilfuza Jonnazarova, AvicennaTajik (2012), “Age features of metabolic syndrome and cardiovascular disorders in gout”, Arthritis Research & Therapy, 14 (Suppl 1 - P69), pp. 49.
10.
10. Vazquez-Mellado J., Garcia C. G., Vazquez S. G., Medrano G., Ornelas M., Alcocer L., Marquez A., Burgos-Vargas R. (2004), “Metabolic syndrome and ischemic heart disease in gout”, J Clin Rheumatol, 10 (3), pp. 105-9.
11.
11. Whitworth J. A. (2003), “2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension”, J Hypertens, 21 (11), pp. 1983-92.
12.
12. Wong Rose, Davis Aileen M., et al (2010), prevalence of arthritis and rheumatic diseases around the world a growing burden and implications for Health Care Needs.

Tác giả

Lưu Thị Bình: Trường Đại học Y Dược Thái Nguyên; Võ Thị Ngọc Anh: Trường Đại học Y Dược Thái Nguyên;
No translate

Files

Article Views572
Document Views1
Downloads13
Section NGHIÊN CỨU LÂM SÀNG
Category TĂNG HUYẾT ÁP
Pages 183-190
Copyright Holder 2014 Tạp chí Tim mạch học Việt Nam